Standard
Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. / Rauch, T; Graefe-Mody, U; Deacon, Carolyn F.; Ring, A; Holst, Jens Juul; Woerle, H-J; Dugi, KA; Heise, T.
In:
Diabetes Therapy, Vol. 3, No. 1, 2012, p. 10.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Rauch, T, Graefe-Mody, U
, Deacon, CF, Ring, A
, Holst, JJ, Woerle, H-J, Dugi, KA & Heise, T 2012, '
Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.',
Diabetes Therapy, vol. 3, no. 1, pp. 10.
https://doi.org/10.1007/s13300-012-0010-yAPA
Rauch, T., Graefe-Mody, U.
, Deacon, C. F., Ring, A.
, Holst, J. J., Woerle, H-J., Dugi, KA., & Heise, T. (2012).
Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. Diabetes Therapy,
3(1), 10.
https://doi.org/10.1007/s13300-012-0010-yVancouver
Rauch T, Graefe-Mody U
, Deacon CF, Ring A
, Holst JJ, Woerle H-J et al.
Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. Diabetes Therapy. 2012;3(1):10.
https://doi.org/10.1007/s13300-012-0010-yAuthor
Rauch, T ; Graefe-Mody, U ; Deacon, Carolyn F. ; Ring, A ; Holst, Jens Juul ; Woerle, H-J ; Dugi, KA ; Heise, T. / Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. In: Diabetes Therapy. 2012 ; Vol. 3, No. 1. pp. 10.
Bibtex
@article{44d67a0aab4045afbd3c7f0d7390df40,
title = "Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.",
author = "T Rauch and U Graefe-Mody and Deacon, {Carolyn F.} and A Ring and Holst, {Jens Juul} and H-J Woerle and KA Dugi and T Heise",
year = "2012",
doi = "10.1007/s13300-012-0010-y",
language = "English",
volume = "3",
pages = "10",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer",
number = "1",
}
RIS
TY - JOUR
T1 - Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.
AU - Rauch, T
AU - Graefe-Mody, U
AU - Deacon, Carolyn F.
AU - Ring, A
AU - Holst, Jens Juul
AU - Woerle, H-J
AU - Dugi, KA
AU - Heise, T
PY - 2012
Y1 - 2012
U2 - 10.1007/s13300-012-0010-y
DO - 10.1007/s13300-012-0010-y
M3 - Journal article
VL - 3
SP - 10
JO - Diabetes Therapy
JF - Diabetes Therapy
SN - 1869-6953
IS - 1
ER -
